Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Dose-scheduling, Observer-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of Vi-DT Conjugate Vaccine in 6-23-Month Old Healthy Filipino Infants and Toddlers

NCT03527355 is registered in ClinicalTrials.gov with International Vaccine Institute as lead sponsor.

NCT NCT03527355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03527355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Dose-scheduling, Observer-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of Vi-DT Conjugate Vaccine in 6-23-Month Old Healthy Filipino Infants and Toddlers
Lead sponsor
International Vaccine Institute
Phase
Phase 2
Overall status
Completed
Start date
April 18, 2018
Completion date
January 19, 2021
Enrollment
285 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

typhoid